Immusoft Receives Rare Pediatric Disease Designation for Treatment of MPS I
RBV Capital is a dedicated life sciences venture capital fund established in 2014 investing into innovative biomedical projects globally
At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline